STC-Technology – Brenus Pharma

AN INNOVATION TO MIMIC PATIENT'S RELAPSING CONDITIONS

EDUCATING IMMUNE SYSTEM TO ANTICIPATE RELAPSE MECHANISMS

aQualitative cancer-related proteins overexpressed.

By stimulation of selected tumor cell lines with standards of care used in the targeted indication.

RT: MUC1 (CRC)

Mucine; Cell Surface Associated – Overexpression associated with carcinomas

RT: MDR1 (CRC)

ATP efflux pump – Therapeutic resistance

TP: EPCAM

Marker for carcinoma – Fast growing epithelial tumors

RT: ABCC1

ABC transporter – Multiple Therapeutics resistance

TS: ICAM1 (CRC)

Widely expressed in tumor cells – Tumor progression

… 100+ Validated by multi-omics analysis.

ENSURING IMMUNE SYSTEM ACTIVATION

bHaptenation: boosting antigen's immune recognition.

cAllogeneic tumor ghost cells

FIRST-IN-CLASS TUMOR ANTIGEN-FOCUSED IMMUNOTHERAPY

Anticipating tumor plasticity from early stage to relapsing disease.

STC TECHNOLOGY EDUCATES IMMUNE SYSTEM TO RECOGNIZE AND ANTICIPATE ESCAPE MECHANISMS IN COLD TUMOR.

What happens in vivo after ID injection ?

Step 1

APC* Cross priming activation

Petient's Dentritic Cells maturation with no HLA restriction.
(*Antigen-Presenting Cell ; Dentritic Cells)

Step 2

TILs education

TILs (Tumor-Inflitrating Lymphocytes) pool generation multispecific of resistance factors: TAA/TSA.
(TAA = Tumor Associated Antigens & TSA = Tumor Specific Antigens)

Step 3

TILs expansion

The Multi specific TILs Pool generated expands, ready for TSA/TAA recognition.

Step 4

Patient's resistance tumor cells' destruction

TILs synergize on multiple qualitative targets and enhance immune modulators repsonse in combination.

A LIMITLESS POTENTIAL TO GENERATE FIRST-IN-CLASS IMMUNOTHERAPIES

Cell lines selection from tumor banks :

PROVIDING A UNIQUE
VALUE PROPOSAL IN THE FIELD

Ready to use, standardized & scalable

Defined biological raw material (cell banks)
GLP/GMP Pharmaceutical development & Pre scale-up validated

FDA PRE IND & FAMHP (EMA) Scientific advises passed

Quick generation of First-In-Class Therapies

Patented platform, protected in key countries

Limitless potential to generate a strong pipeline

LEVERAGING OUR PLATFORM TO GENERATE STRONG CANDIDATES.

INTERESTED
IN OUR TECHNOLOGY ?

STAY TUNED

NEWS

Media

20 September 2024

The Times Magazine : Brenus Pharma Secures $25 Million to Propel Clinical Trials for Precision Cancer Vaccines

Media

19 September 2024

EU Startup – Lyon-based Brenus Pharma raises €22.2 million for precision cancer vaccines

Media

18 September 2024

BMF Business (FR) French Tech : Vaccins, futur de la lutte contre le cancer ?

Media

18 September 2024

Les Echos (FR) – Brenus Pharma réunit 22 millions pour lancer les essais cliniques de son vaccin anticancer

Team

13 June 2024

It’s a wrap San Diego! #BIO2024

Events

13 June 2024